Subunit aMPV-B vaccine candidate shows strong immune response
Bottom line
A new Frontiers in Veterinary Science study reports that researchers in Kazakhstan developed a subunit vaccine candidate targeting avian metapneumovirus subtype B, and, in an experimental chicken study, it outperformed a commercial live vaccine on several immune markers. The vaccine, built from purified aMPV-B glycoproteins and formulated with Montanide ISA 70 VG, produced 100% seroconversion by day 14, along with higher IgG and virus-neutralizing antibody titers than the live comparator. Neutralizing titers were reported as eightfold higher after the first dose and 16-fold higher after the booster, and the vaccine also increased IFN-γ and IL-4 expression, suggesting both Th1 and Th2 immune activation. (frontiersin.org)
Why it matters: For veterinary professionals in poultry health, the study adds to growing interest in alternatives to live aMPV vaccines at a time when subtype B remains an active field problem in multiple regions. In Ontario, for example, commercial poultry cases have continued through 2025 and into 2026, with about 92% of PCR-positive submissions identified as subtype B, while U.S. regulators have already taken emergency steps to speed access to aMPV vaccines, including experimental autogenous inactivated products and imported seed stock for domestic live-vaccine production. A subunit platform could be attractive because it may avoid some concerns associated with live products, including reversion-to-virulence risk, but this paper stops short of showing protection in challenge studies or under commercial conditions. (uoguelph.ca)
What to watch: The next key question is whether this candidate can demonstrate real-world protection in challenge and field trials, especially across diverse circulating strains. (frontiersin.org)
Key facts
- Study type
- Experimental chicken study
- Pathogen
- Avian metapneumovirus subtype B
- Vaccine type
- Subunit vaccine candidate
- Vaccine components
- Purified aMPV-B glycoproteins, Montanide ISA 70 VG
- Comparator
- Commercial live vaccine
- Seroconversion
- 100% by day 14
- Neutralizing antibodies
- Eightfold higher after first dose, 16-fold higher after booster
- Immune markers
- Higher IgG, IFN-γ, and IL-4 expression
- Study limitation
- No challenge or commercial field testing
A newly published study in Frontiers in Veterinary Science describes a subunit vaccine candidate against avian metapneumovirus subtype B that generated stronger immune responses in chickens than a commercial live vaccine. The researchers reported 100% seroconversion by day 14, significantly higher IgG and virus-neutralizing antibody titers, and increased expression of IFN-γ and IL-4 after vaccination, positioning the candidate as a potentially important new approach for aMPV-B control. (frontiersin.org)
The work arrives as aMPV continues to draw attention across commercial poultry systems. The Frontiers paper notes that aMPV subtype B remains a major respiratory pathogen despite widespread vaccination efforts, and the authors based their vaccine on a field isolate recovered during surveillance of 115 chicken flocks from 16 commercial farms in Kazakhstan in 2024 and 2025. Outside Kazakhstan, recent surveillance in Ontario has shown continued poultry detections through 2025 and into 2026, with subtype B accounting for roughly 92% of PCR-positive submissions, underscoring that this is not just a localized issue. (frontiersin.org)
Technically, the vaccine used purified aMPV-B glycoproteins formulated with the oil adjuvant Montanide ISA 70 VG in a water-in-oil emulsion. The study compared the candidate with a commercial live vaccine in a prime-boost regimen in chickens. According to the paper, the subunit product induced 100% seroconversion by day 14 and produced neutralizing antibody titers that were eightfold higher after primary immunization and 16-fold higher after booster immunization than the live-vaccine group. The formulation contained 10 μg of antigen per dose and was administered intramuscularly at 350 μL per bird. (frontiersin.org)
The immune signal went beyond antibody levels. The authors reported significantly enhanced IFN-γ and IL-4 expression, which they interpreted as evidence of both Th1- and Th2-mediated responses. That matters because balanced cellular and humoral immunity is often seen as important for respiratory virus protection. At the same time, the study's own limitations are important: the researchers did not test protective efficacy in homologous or heterologous challenge models, did not assess performance under commercial production conditions, and did not establish cross-protection against genetically diverse strains. (frontiersin.org)
Industry and regulatory context makes the findings more relevant. In the U.S., USDA APHIS says the Center for Veterinary Biologics has, for the first time, authorized experimental autogenous inactivated vaccine use for aMPV to speed product availability, and has also allowed import of master seed and master cell stock to accelerate domestic production of live products. Separately, USPOULTRY announced completion of a research project at South Dakota State University that developed live and inactivated U.S.-strain aMPV-B vaccine candidates, with strong protection reported in chickens and turkey poults. Together, those developments suggest a broader push toward expanding the vaccine toolbox as the virus re-emerges in North American production systems. (aphis.usda.gov)
Why it matters: For veterinarians serving poultry operations, this paper is less a practice-changing result than an early signal about where vaccine development may be heading. Subunit vaccines offer theoretical advantages in safety and antigen design, and the authors explicitly frame them as a way to avoid reversion-to-virulence risk associated with live products. That could resonate in a disease area where vaccine choice, field strain match, maternal antibody interference, and diagnostic interpretation all matter. But immunogenicity is only part of the story. Until challenge protection, duration of immunity, mucosal responses, and field performance are demonstrated, veterinary decision-making will still rest mainly on currently available live, inactivated, or autogenous options, plus surveillance and biosecurity. (frontiersin.org)
There also isn't much outside expert reaction yet tied specifically to this paper, which was published on August 13, 2026. Still, the broader literature and current field activity point in the same direction: aMPV-B remains epidemiologically important, and vaccine innovation is moving quickly. In that sense, this study may be most useful as proof that a non-live platform can generate a strong immune response worth taking into the next phase of development. (frontiersin.org)
What to watch: The next milestones are straightforward: experimental challenge data, broader strain-coverage work, and commercial field studies that show whether the stronger lab immune readouts translate into fewer clinical signs, lower transmission, or better production outcomes. (frontiersin.org)